- Home
- DCGO vs ESLA Comparison
DCGO vs ESLA Comparison
Compare DCGO & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCGO | ESLA |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 45.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | DCGO | ESLA |
|---|---|---|
| Price | $0.60 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.38 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.3M | 36.6K |
| Earning Date | 05-11-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $322,196,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.78 |
| 52 Week High | $1.78 | $3.15 |
Technical Indicators
Market Signals| Indicator | DCGO | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 45.12 |
| Support Level | $0.47 | $0.97 |
| Resistance Level | $0.65 | $1.31 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 91.21 | 42.96 |
Price Performance
Historical ComparisonAbout DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.